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Summary
Aim To estimate the prevalence of self-reported drug allergy in adults.
Methods Cross-sectional survey of a general adult population from Porto (all of whom were living
with children involved in the International Study of Asthma and Allergies in Childhood–phase
three), during the year 2002, using a self-administered questionnaire.
Results The prevalence of self-reported drug allergy was 7.8% (181/2309): 4.5% to penicillins or
other b-lactams, 1.9% to aspirin or other non-steroidal anti-inﬂammatory drugs (NSAIDs) and
1.5% to other drugs. In the group ‘allergic to b-lactams’, the most frequently implicated drug was
penicillin G or V (76.2%) followed by the association of amoxicillin and clavulanic acids (14.3%). In
the group ‘allergic to NSAIDs’, acetylsalicylic acid (18.2%) and ibuprofen (18.2%) were the most
frequently identiﬁed drugs, followed by nimesulide and meloxicam. Identiﬁcation of the exact name
of the involved drug was possible in less than one-third of the patients, more often within the NSAID
group (59.5%). Women were signiﬁcantly more likely to claim a drug allergy than men (10.2% vs.
5.3%). The most common manifestations were cutaneous (63.5%), followed by cardiovascular
symptoms (35.9%). Most of the reactions were immediate, occurring on the ﬁrst day of treatment
(78.5%). Only half of the patients were submitted to drug allergy investigations. The majority
(86.8%) completely avoided the suspected culprit drug thereafter.
Conclusions The results showed that self-reported allergy to drugs is highly prevalent and poorly
explored. Women seem to be more susceptible. b-lactams and NSAIDs are the most frequently
concerned drugs.
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Introduction
Drug hypersensitivity reactions are the side-effects of drugs
taken at a dose that is tolerated by normal subjects and which
clinically resemble allergy. When immunologic mechanisms
are involved, these reactions are classiﬁed as drug allergy [1].
However, many people having experienced a drug hypersensi-
tivity reaction are catalogued as allergic to the drug without any
further investigation [2–5]. The diagnostic work-up of a drug
hypersensitivity reaction is indeed difﬁcult [5]. The reaction
itself is rarely documented, many factors besides the drug can
be involved; sometimes the reaction occurred a long time ago
and sensitivity could be lost. Another problem is the lack of
consensual diagnostic procedures for many drugs, although
efforts are being made to overcome this problem [6, 7].
Epidemiological studies about the prevalence of adverse
drug reactions, including hypersensitivity, have been focussed
mainly on hospitalized patients, hospital admissions and
pharmacovigilance post-marketing drug monitoring pro-
grammes. It has been estimated that 3–6% of all hospital
admissions are because of adverse drug reactions [8–11] and
that about 2–20% of hospitalized patients experience some
adverse drug reactions [8, 10, 12–15]. In outpatients, the
reported incidence of adverse drug reactions can reach 15%
[16, 17] and it is also well known that only few reactions are
reported to pharmacovigilance agencies [12, 18]. Drug
hypersensitivity reactions are thought to represent up to
one-third of adverse drug reactions [3]. Surprisingly, studies
concerning the prevalence in the general population of
adverse drug reactions in general and drug hypersensitivity
reactions in particular are scarce compared with studies
concerning other allergic diseases, but it may be estimated
that 3–7% of the population experience an adverse drug
reaction [3, 16, 17, 19]. On the other hand, it is consensual
that adverse drug reactions cause signiﬁcant morbidity and
mortality besides huge direct and indirect costs [2, 8, 11, 20].
The role of drug hypersensitivity reactions in that respect is
completely unknown.
The aim of this study was to assess the prevalence of self-
reported drug allergy in a Portuguese population, with a
special focus on b-lactam antibiotics and non-steroidal anti-
inﬂammatory drugs (NSAIDs) [4, 21–25].
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Material and methods
Design of the study
This is a cross-sectional survey of a general adult population
from Porto during the year 2002. Two thousand ﬁve hundred
subjects were invited to complete a self-administered ques-
tionnaire to assess the life occurrence of drug hypersensitivity
events in adults. The sample consisted of adults (mostly
parents) living with children who were participating in the
International Study of Asthma and Allergies in Childhood
(ISAAC) phase three study in Porto. Children aged 6–7 years
were chosen randomly from Porto public schools according
to the ISAAC protocol [26]. The term ‘allergy’ was used in the
questionnaire, as it is the most recognized term among the
general population (even though drug hypersensitivity would
probably be more accurate). Detailed information about the
reaction (or the most serious episode if several) was used to
better characterize the reactions in terms of clinical symptoms
and severity. Information about a previous diagnostic work-
up was also analysed.
Statistical analysis
All analyses were performed with the SPSS statistical package
(version 11.0) and a two-sided signiﬁcance level of 5% was
used throughout. For the characterization of the study
population, a descriptive analysis was done. The prevalence
of responses was compared with the Pearson w2 test (with the
Yates correction when applied) or the Fisher exact test when
needed. The odds ratio (OR) and its 95% conﬁdence interval
(CI) were also calculated. The Wilcoxon–Mann–Whitney test
and Kruskal–Wallis one-way ANOVA were used to compare
the age between two or more groups, respectively.
Results
General sample
We evaluated 2309 individuals ranging from 21 to 83 years
(mean 36.9  6.1 years) with an approximately equal
distribution between sexes (48.4% males). The rate of
participation was 92.4% (2309/2500). The prevalence of
self-reported drug allergy was 7.8% (181/2309): 4.5%
considered themselves allergic to penicillins or other b-
lactams, 1.9% to aspirin or other NSAIDs and 1.5% stated
to be allergic to other drugs. Women were signiﬁcantly more
likely to have self-reported drug allergy (OR5 2.05,
Po0.001, 95% CI5 1.04–2.82) and to be allergic to b-
lactams (OR5 2.08, P5 0.001, CI 1.36–3.17), but not signiﬁ-
cantly higher to NSAIDs (Table 1). There were no signiﬁcant
age differences between the individuals with or without self-
reported drug allergy and also between the individuals with
self-reported drug allergy to b-lactams or NSAIDs.
Subjects with self-reported drug allergy
The 181 subjects with self-reported drug allergy were aged
from 24 to 64 years (mean 36.9  6.4 years) and 67.9% were
women. Among this population, 96 (53.0%) considered
themselves to be allergic to b-lactams, 37 (20.4%) to NSAIDs
and eight (4.4%) to both. Regarding other drugs responsible,
pomades were involved in eight (4.4%) subjects, sulphame-
toxazol/trimetroprim and other antibiotics in four (2.2%) and
ﬁve (2.8%) individuals, respectively. The identiﬁcation of the
drug was not given by eight subjects (4.4%). There were no
signiﬁcant gender differences between the individuals with
self-reported drug allergy to b-lactams or NSAIDs. From the
171 subjects that answered the question about the way the
diagnosis was made, 50 (29.3%) stated that they have been
told by the doctor they were allergic. About half of the
subjects (67 out of the 123 who answered the question) had
not been submitted to any diagnostic procedure, 26%
underwent blood analysis and 22.7% skin testing.
In the group ‘allergic only to b-lactams’, 21/96 (21.9%)
recalled the exact drug that caused the reaction and the most
frequently implicated was penicillin G or V (76.2%), followed
by the association amoxicillin/clavulanic acid (14.3%). In the
group ‘allergic to NSAIDs’, 22/57 (59.5%) could remember
the exact drug involved in the reaction. Acetylsalicylic acid
and ibuprofen were identiﬁed by eight subjects (18.2%).
Nimesulide was mentioned by three participants and melox-
icam by two. People considering themselves allergic to
NSAIDs identiﬁed more often the name of the involved drug
than the ones with reactions to b-lactams (OR5 5.24,
Po0.001, 95% CI5 2.32–11.84).
Recalled clinical manifestations (Table 2) were separated
into cutaneous, nasal/ocular, bronchial, cardiovascular and
digestive reactions. The most common manifestations were
cutaneous (63.5%), followed by cardiovascular (35.9%),
bronchial (14.4%), nasal/ocular (12.7%) and gastrointestinal
symptoms (11.6%). Comparisons between individuals with
self-reported b-lactam and NSAID allergy showed only
signiﬁcant differences for the frequency of gastrointestinal
symptoms: 6.3% in the b-lactam group vs. 24.3% in the
NSAID group (P5 0.006). Women reported symptoms more
often than men, but this difference was only signiﬁcant for
gastrointestinal symptoms (OR5 5.26, P5 0.031, 95%
CI5 1.18–23.39) and marginally signiﬁcant for cardiovascu-
lar symptoms (OR5 2.04, P5 0.06, 95% CI5 1.02–4.05)
(Table 3).
Only 125/181 (69.1%) subjects with self-reported drug
allergy answered the question about the route of administra-
tion of the drug, which was oral for 56%, parental for 40%
and both oral and parental for ﬁve (4%) individuals.
Table 1. Differences in self-reported drug allergy in women and men
No. (%) with
hypersensitivity OR (95% CI) P–value
Any drugs
Women 122/1192 (10.2) 2.05 (1.04. 2.82) o 0.001
Men 59/1117 (5.3)
NSAIDs
Women 29/1192 (2.4) 1.61 (0.88. 2.95) 40.05
Men 17/1117 (15)
b-Lactams
Women 71/1192 (6.0) 2.08 (1.36. 3.17) 0.001
Men 33/1117 (3.0)
OR, odds ratio; CI, confidence interval; NSAIDs, non-steroidal anti-inflamma-
tory drugs.
1598 E. Gomes et al.
r 2004 Blackwell Publishing Ltd, Clinical and Experimental Allergy, 34:1597–1601
Out of 153, 114 (74.5%) did not recall a previous contact
with the same drug. For the 139 individuals who answered
this question, the reaction occurred during the ﬁrst day of
treatment for 69.1%. According to the 144 valid answers, the
time delay between the last intake of the drug and the
reaction was less than 1 h in 43.1% of the cases, more than 1h
but less than 1 day in 35.4% and more than 24h in 21.5%.
Women and men did not report different times. There was a
signiﬁcant association between the route of administration
and the time to reaction (P5 0.017) with the parental route
being responsible for more reactions occurring within the ﬁrst
hour (58.7% vs. 35.3%) (Table 4). There was no signiﬁcant
association between the time interval of the intake and the
reaction among reactants to b-lactams vs. NSAIDs, although
38.7% of the latter group reacted within 1 h vs. 53.5% in the
former group. In fact, in 57.8% of the b-lactam group the
parental route was used as compared with only 20.8% in the
NSAID group (P5 0.004).
In 57.5% (85 out of 148 who answered this question) of the
individuals, it took more than 1 day to recover completely
from the reaction. Only 62.6% (92 out of 147) looked for
medical assistance because of the reaction. Although not
signiﬁcant, there was a tendency within the group with
isolated cutaneous manifestations to look for medical help
more often than those with other manifestations (OR5 2.39,
P5 0.08, 95% CI5 0.99–5.78).
The majority of subjects (86.8%, 138 out of 159 who
answered this question) completely avoided the suspected
culprit drug thereafter, and 20 out of the 21 (13.2%) who
took it again relapsed. Only 13.3% (24 of 181) of the
participants stated that they would like to further investigate
the reaction.
Discussion
The prevalence of self-reported drug allergy in a general
population has never been reported in the literature.
Surprisingly, it was not lower (7.8%) than the prevalence
for inpatients. Similarly, except for NSAIDs, women were
more frequently concerned than men [27–30]. The high rate of
participation (92.4%) strengthens the data. If we consider
that non-returned or unanswered questionnaires would be
from people without self-reported drug allergy the prevalence
is still high (181/2500, 7.2%).
In agreement with other studies [8, 21–23, 30], the drugs
suspected to be responsible for most self-reported drug
allergies were b-lactams and NSAIDs. It must be said that
the consumption of antibiotics and NSAIDs in Portugal is
one of the highest in Europe and that most of the drugs are
easily obtained over the counter [24, 25]. Most of the people
with a reported drug allergy to any b-lactam will consider
themselves allergic to all penicillins and do not recall the exact
drug name, although speciﬁc reactions to different molecules
are possible [31–34]. This reﬂects in fact the common medical
practice in Portugal and in other countries of banning all b-
lactams in patients who experienced a reaction to one
Table 2. Relative frequency of clinical manifestations, as reported by the
subjects (n5 181)
Question % Question %
Itching on the skin 30.4 Sweating, fainting 21.5
Skin rash or urticaria 47.5 Hypotension 13.3
Swelling or angiooedema 20.4 Loss of consciousness 8.8
Redness, itching or
secretion of the eyes
6.6 Tachycardia /palpitations 11.6
Sneezing, itching, blockage
or secretion of the nose
10.5 Difficulty to swallow or to speak 6.1
Shortness of breath or
cough
13.3 Nausea or stomach-ache 7.7
Wheezing 6.6 Vomiting or diarrhoea 7.2
Pallor 12.7 Other symptoms 9.4
Table 4. Chronology of the reactions according to the route of administration
and the type of drugs (b-lactams or NSAIDs)
No. (%) with manifestation
o 1 h 1 h to 1 day 41 day Total P-value
Administration
Oral medication 24 (35.3) 26 (38.2) 18 (26.5) 68 (100.0) 0.017
Parental route 27 (58.7) 15 (32.6) 4 (8.7) 46 (100.0)
Drugs
b-Lactams 38 (53.5) 25 (35.2) 8 (11.3) 71 (100.0) 40.05
NSAIDs 12 (38.7) 13 (41.9) 6 (19.4) 31 (100.0)
NSAIDs, non-steroidal anti-inflammatory drugs.
Table 3. Differences in clinical manifestations during the episode of self-
reported drug allergy between b-lactam and NSAID groups and between
women and men
Manifestations
No. (%) with
manifestation OR (95% CI) P-value
Cutaneous
b-Lactams 61/96 (63.5) 2.05 (0.95. 4.42) 0.09
NSAIDs 17/37 (45.9)
Women 79/122 (64.8) 1.17 (0.62. 2.23) 40.05
Men 36/59 (61.0)
Nasal/ocular
b-Lactams 11/96 (11.5) 0.67 (0.23. 1.96) 40.05
NSAIDs 6/37 (16.2)
Women 18/122 (14.8) 1.87 (0.66. 5.31) 40.05
Men 5/59 (8.5)
Bronchial
b-Lactams 13/96 (13.5) 1.29 (0.39. 4.25) 40.05
NSAIDs 4/37 (10.8)
Women 19/122 (14.8) 1.37 (0.54. 3.47) 40.05
Men 7/59 (11.9)
Cardiovascular
b-Lactams 29/96 (30.2) 0.71 (0.32. 1.57) 40.05
NSAIDs 14/37 (37.8)
Women 50/122 (41.0) 2.04 (1.02. 4.05) 0.06
Men 15/59 (25.4)
Gastrointestinal
b-Lactams 6/96 (6.3) 0.21 (0.07. 0.63) 0.006
NSAIDs 9/37 (24.3)
Women 19/122 (15.6) 5.26 (1.18. 23.39) 0.031
Men 2/59 (3.4)
NSAIDs, non-steroidal anti-inflammatory drugs.
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antibiotic of this group without any diagnostic work-up [3–5,
21, 35–37]. On the other hand, people with a reported drug
allergy to a NSAID will recall more exactly the drug involved
and do not assume so easily that they should avoid the whole
group. This again reﬂects common medical practice in
Portugal and other countries where NSAIDs are usually
considered safe in patients having experienced a cutaneous
hypersensitivity reaction to aspirin; nimesulide [38, 39] or
meloxicam [40, 41] are frequently proposed instead.
Regarding manifestations, skin reactions of immediate
delay were the vast majority as stated by others [4, 14, 23,
42]. The fact that most reactions occurred during the ﬁrst day
of treatment and within 1 h of drug administration suggests
that IgE-dependent reactions are more frequent than T cell-
dependent reactions. The fact that the majority of the
individuals do not recall a previous contact with the drug
suspected to be causing the reaction could be explained by
several factors: a long time interval since the sensitizing
treatment, unperceived intakes of the same or similar drugs or
by the occurrence of non-allergic reactions.
Many people did not seek medical help because of the
reaction. Only 62.6% did so, and were the ones with pure
dermatological manifestations that more often looked for
assistance. After a possible allergic reaction, most people
avoided further contact with the suspected causative drug and
only 13.2% took it again. Among those, the majority had
another reaction, demonstrating true drug hypersensitivity. A
ﬁrm diagnosis was approached with the help of blood
analyses and/or skin testing in less than half of the cases
and about half were apparently not submitted to any
diagnostic investigation. This might be due either to a low
number of centres exploring drug allergy or to the fact that
most of the people were convinced about their diagnosis
(since only 13.3% of the participants referred that they would
like to be contacted to further investigate the reaction).
This study shows that self-reported drug allergy is highly
prevalent in the adult Portuguese population, women being
more susceptible. Dermatological reactions are the most
frequent. Drug hypersensitivity reactions are, however,
poorly investigated in many cases, leading to an uncertain
diagnosis of allergy and possibly to the prescription of
potentially less effective and/or more toxic drugs. Direct and
indirect costs are not evaluated [35–37, 43].
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